A Phase I/II Trial of Intensity Modulated Radiation (IMRT) Dose Escalation With Concurrent Fixed-dose Rate Gemcitabine (FDR-G) in Patients With Unresectable Pancreatic Cancer

<i>DPC4</i> Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer

Christine A. Iacobuzio–Donahue, Baojin Fu, Shinichi Yachida et al. · Journal of Clinical Oncology · 2009 · 1.1K citations · Full text

Medicine, Oncology, Pathology +17

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.

James L. Abbruzzese, Ralf Grunewald, Elizabeth A. Weeks et al. · Journal of Clinical Oncology · 1991 · 759 citations

Medicine, Oncology, Pharmacology +13

Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study

Bruno Chauffert, F. Mornex, F. Bonnetain et al. · Annals of Oncology · 2008 · 694 citations

Medicine, Oncology, Radiation Oncology +15

Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities

Ying Kuen Cheung, Rick Chappell · Biometrics · 2000 · 534 citations

Medicine, Biostatistics, Oncology +13

Randomized Phase II Comparison of Dose-Intense Gemcitabine: Thirty-Minute Infusion and Fixed Dose Rate Infusion in Patients With Pancreatic Adenocarcinoma

Margaret A. Tempero, William Plunkett, Veronique Ruiz van Haperen et al. · Journal of Clinical Oncology · 2003 · 522 citations

Pharmacy, Oncology, Pharmacokinetics +16